The rapid shift of vaping from smoking cessation aid to widespread youth recreation creates unprecedented respiratory health challenges that pediatric specialists must now navigate daily. What began as harm reduction has evolved into a distinct public health crisis affecting a generation with no prior smoking history. Emerging clinical evidence directly associates adolescent e-cigarette use with asthma development, bronchiolitis episodes, and early markers of chronic obstructive pulmonary disease. The pulmonary toxicity stems not only from nicotine but from chemical decomposition products created when e-liquids are heated, producing compounds never intended for inhalation. Youth users experience increased respiratory symptoms and measurable lung function changes, suggesting damage patterns that mirror but differ from traditional tobacco-related disease. The adolescent perception that vaping carries minimal risk contradicts mounting clinical observations of immediate respiratory effects. This disconnect between perceived safety and emerging evidence places pediatric pulmonologists at the frontline of both diagnosis and education. The challenge extends beyond individual patient care to broader public health advocacy, as regulatory approaches worldwide show inconsistent effectiveness. Unlike adult smoking cessation where decades of research inform treatment protocols, evidence-based vaping cessation interventions for adolescents remain largely undeveloped. The urgency lies not just in treating current respiratory complications, but in preventing a new trajectory of chronic lung disease in patients whose lifelong respiratory health trajectories are still being established. This represents a unique generational health challenge requiring immediate clinical attention and long-term research commitment.